Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BNOS 2022 | Evaluating the prevalence of BRAF V600E mutations in glioblastoma

Lily Andrews, University of Bristol, Bristol, UK, comments on the findings from a study assessing the prevalence of BRAF V600E mutations in patients with glioblastoma. The most common subtypes that were found to have BRAF V600E mutations were epithelioid glioblastomas, pleomorphic xanthoastrocytoma (PXA), ganglioglioma and anaplastic ganglioglioma. The aforementioned forms of glioma are additionally more frequent in pediatric patients and randomized clinical trials should be undertaken to assess the efficacy of BRAF inhibitors in this group of patients. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.